{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:44Z","timestamp":1792839704281,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-HK-987-6069"],"award-info":[{"award-number":["IN-HK-987-6069"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12072-022-10402-y","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T06:18:47Z","timestamp":1662617927000},"page":"1318-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug\u2013drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study"],"prefix":"10.1007","volume":"16","author":[{"given":"Vicki Wing-Ki","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Langjun","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Shuk Man","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Kit","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Che-To","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"10402_CR1","unstructured":"World Health Organization. Global hepatitis report 2017. Website: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/. Accessed on 20 Apr 2021."},{"issue":"3","key":"10402_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"HCVC Polaris Observatory","year":"2017","unstructured":"Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u2013176","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10402_CR3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/jgh.14622","volume":"34","author":"GL Wong","year":"2019","unstructured":"Wong GL, Chan HL, Loo CK, et al. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol. 2019;34(9):1641\u20131647","journal-title":"J Gastroenterol Hepatol"},{"key":"10402_CR4","unstructured":"Department of Health HG. Hong Kong Viral Hepatitis Action Plan 2020\u20132024. October 2020. Website: https:\/\/www.hepatitis.gov.hk\/doc\/action_plan\/Action%20Plan_Full%20Version_PDF_en.pdf. Accessed on 20 Apr 2021."},{"key":"10402_CR5","unstructured":"Department of Health HG. Surveillance of Viral Hepatitis in Hong Kong \u2013 Update Report. Hong Kong; 2019. Website: https:\/\/www.chp.gov.hk\/files\/pdf\/viral_hep_sur_report_2019.pdf. Accessed on 30 Sep 2021."},{"issue":"11","key":"10402_CR6","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/liv.13926","volume":"38","author":"YT Hui","year":"2018","unstructured":"Hui YT, Wong GLH, Fung JYY, et al. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int. 2018;38(11):1911\u20131919","journal-title":"Liver Int"},{"issue":"9","key":"10402_CR7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-2036.2010.04269.x","volume":"31","author":"R Mac Nicholas","year":"2010","unstructured":"Mac Nicholas R, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon\/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther. 2010;31(9):929\u2013937","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10402_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/apt.13514","volume":"43","author":"D Banerjee","year":"2016","unstructured":"Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther. 2016;43(6):674\u2013696","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10402_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.002","volume":"69","author":"J Vermehren","year":"2018","unstructured":"Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178\u20131187","journal-title":"J Hepatol"},{"issue":"8","key":"10402_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/apt.13769","volume":"44","author":"J Vermehren","year":"2016","unstructured":"Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856\u2013865","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10402_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","volume":"10","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Burton JR Jr, Everson GT. Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596\u2013606","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11\u201312","key":"10402_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/apt.12523","volume":"38","author":"B Maasoumy","year":"2013","unstructured":"Maasoumy B, Port K, Calle Serrano B, et al. The clinical significance of drug\u2013drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther. 2013;38(11\u201312):1365\u20131372","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10402_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bcp.13095","volume":"83","author":"S Talavera Pons","year":"2017","unstructured":"Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83(2):269\u2013293","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10402_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100152","volume":"2","author":"VW Hui","year":"2020","unstructured":"Hui VW, Chan SL, Wong VW, et al. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP Rep. 2020;2(6): 100152","journal-title":"JHEP Rep"},{"issue":"1","key":"10402_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","volume":"158","author":"TC Yip","year":"2020","unstructured":"Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158(1):215\u2013225 (e6)","journal-title":"Gastroenterology"},{"key":"10402_CR16","unstructured":"Authority H. Hospital authority drug formulary (HADF). Website: https:\/\/www.ha.org.hk\/hadf\/en-us\/Updated-HA-Drug-Formulary\/Drug-Formulary.html. Accessed on 30 Sep 2021."},{"key":"10402_CR17","unstructured":"Liverpool Uo. Interaction charts for directly acting antivirals and ribavirin. University of Liverpool. Website: https:\/\/www.hep-druginteractions.org\/checker. Accessed on 30 Sep 2021."},{"issue":"1","key":"10402_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/jtim-2017-0007","volume":"5","author":"A Geddawy","year":"2017","unstructured":"Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5(1):8\u201317","journal-title":"J Transl Int Med"},{"issue":"2","key":"10402_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa040","volume":"7","author":"B Schulte","year":"2020","unstructured":"Schulte B, Wubbolding M, Marra F, et al. Frequency of potential drug-drug interactions in the changing field of HCV therapy. Open Forum Infect Dis. 2020;7(2): ofaa040","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10402_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3350\/cmh.2020.0180","volume":"27","author":"PY Hsu","year":"2021","unstructured":"Hsu PY, Wei YJ, Lee JJ, et al. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clin Mol Hepatol. 2021;27(1):186\u2013196","journal-title":"Clin Mol Hepatol"},{"issue":"13","key":"10402_CR21","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.3390\/ijerph18137144","volume":"18","author":"A Mangia","year":"2021","unstructured":"Mangia A, Scaglione F, Toniutto P, et al. Drug\u2013drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: insights from a real-world study. Int J Environ Res Public Health. 2021;18(13):7144","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10402_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245767","volume":"16","author":"R Boff da Costa","year":"2021","unstructured":"Boff da Costa R, Boff Costa M, Longo L, et al. Direct antiviral agents for hepatitis C and drug interaction risk: a retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLoS ONE. 2021;16(2): e0245767","journal-title":"PLoS ONE"},{"issue":"9","key":"10402_CR23","first-page":"1239","volume":"27","author":"MP Curry","year":"2021","unstructured":"Curry MP, Flamm SL, Milligan S, et al. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. J Manag Care Spec Pharm. 2021;27(9):1239\u20131248","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10402_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11096-019-00876-6","volume":"41","author":"M Coghlan","year":"2019","unstructured":"Coghlan M, O\u2019Leary A, Melanophy G, Bergin C, Norris S. Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort. Int J Clin Pharm. 2019;41(5):1227\u20131238","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"10402_CR25","doi-asserted-by":"publisher","first-page":"300060520964659","DOI":"10.1177\/0300060520964659","volume":"48","author":"A Sicras-Mainar","year":"2020","unstructured":"Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res. 2020;48(10):300060520964659","journal-title":"J Int Med Res"},{"issue":"11","key":"10402_CR26","first-page":"1261","volume":"25","author":"SL Keast","year":"2019","unstructured":"Keast SL, Holderread B, Cothran T, Skrepnek GH. Hepatitis C direct-acting antiviral treatment selection, treatment failure, and use of drug-drug interactions in a state medicaid program. J Manag Care Spec Pharm. 2019;25(11):1261\u20131267","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10402-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T18:24:12Z","timestamp":1701023052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10402-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10402"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10402-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"27 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Henry Chan is an advisor for AbbVie, Aligos, Aptorum, Arbutus, Hepion, Janssen, Gilead, GSK, Merck, Roche, Vaccitech, VenatoRx, Vir Biotechnology; and a speaker for Mylan, Gilead and Roche. Vincent Wong has served as an advisory committee member for 3\u00a0V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Janssen, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, TARGET-NASH and Terns; and a speaker for Bristol-Myers Squibb, Echosens, Gilead Sciences and Merck. He has also received a research grant from Gilead Sciences. Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, as a speaker for Abbott, Abbvie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen and Roche, and received research grant from Gilead Sciences. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Joint Chinese University of Hong Kong\u2014New Territories East Cluster Clinical Research Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research (ethics)"}},{"value":"Because of the retrospective nature of this study and we will have no access to patient identifiers, written informed consent will be waived, subject to approval by the Joint CUHK-NTEC CREC.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate (ethics)"}},{"value":"All the authors are consent to publish the data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish (ethics)"}},{"value":"Not available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials registration"}}]}}